Special Drug Use Investigation of EYLEA for AMD

Trial Profile

Special Drug Use Investigation of EYLEA for AMD

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Nov 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 21 Feb 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 21 Feb 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
    • 16 Dec 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top